Generic Impoyz Availability
Last updated on Apr 10, 2025.
Impoyz is a brand name of clobetasol topical, approved by the FDA in the following formulation(s):
IMPOYZ (clobetasol propionate - cream;topical)
-
Manufacturer: PRIMUS PHARMS
Approval date: November 28, 2017
Strength(s): 0.025% [RLD]
Is there a generic version of Impoyz available?
An Authorized Generic version of Impoyz has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- clobetasol propionate TOPICAL CREAM .25 mg/g
INA Pharmaceutics Inc
NDC Code: 741570710
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Impoyz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical formulations comprising a steroid
Patent 10,064,875
Issued: September 4, 2018
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): PROMIUS PHARMA LLCThe application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030
-
Topical formulations comprising a steroid
Patent 10,588,914
Issued: March 17, 2020
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): ENCORE DERMATOLOGY, INC.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
-
Topical compositions comprising a corticosteroid
Patent 9,855,334
Issued: January 2, 2018
Inventor(s): Kandavilli Sateesh & Bommagani Madhusudhan & Nalamothu Vijendra & Okumu Franklin
Assignee(s): PROMIUS PHARMA LLCTopical compositions comprising a corticosteroid and at least one penetration enhancing agent, wherein the composition is substantially free of propylene glycol.
Patent expiration dates:
- March 11, 2035✓
- March 11, 2035
-
Topical formulations comprising a steroid
Patent 9,956,231
Issued: May 1, 2018
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): DR. REDDY'S LABORATORIES LTD.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030✓✓
- August 31, 2030
More about Impoyz (clobetasol topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical steroids
- Breastfeeding
- En español
Patient resources
Other brands
Temovate, Clobex, Olux, Clodan, ... +10 more
Professional resources
Other brands
Temovate, Clobex, Olux, Clodan, ... +3 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.